Pharmacokinetics of Prostate Cancer Lesions on Dual Time-Point PET/CT: A Predictive Factor for Response to PSMA Radioligand Therapy?
- 12 November 2026
- journal article
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
Abstract
Prostate cancer (PC) lesions usually show increasing uptake of prostate-specific membrane antigen (PSMA) ligands over time. We investigated whether the intensity changes of PSMA-ligand uptake on dual-time-point positron emission tomography/computed tomography (PET/CT) can predict the response to [177Lu]Lu-PSMA radioligand therapy (PSMA-RLT). Nineteen patients who underwent dual-time-point [18F]PSMA-1007 PET/CT before PSMA-RLT were retrospectively analysed. Standardised uptake values were measured for local prostate cancer lesions and lymph node, bone, and organ metastases. These groups were compared for maximum standardised uptake value (SUVmax) differences between standard and late scans. Using Firth’s bias-reduced logistic regression, we assessed whether change in SUVmax between standard and late scans (ΔSUVmax) correlates with long-term biochemical response to PSMA-RLT. We analysed 355 PC lesions (14 local tumours, 171 bone, 132 lymph node, and 38 organ metastases). Across all lesions, the median SUVmax in late scans was 15.2% higher than that in standard scans (p<0.001). A mixed-effects model accounting for clustering within patients suggested differences in relative ΔSUVmax across metastasis types, although these did not reach statistical significance (p=0.058). Logistic regression showed no correlation of ΔSUVmax to therapy response likelihood (odds ratio=1.01, p=0.85). In contrast, the SUVmax of the hottest measured lesion significantly predicted the therapy response (odds ratio=1.11 per unit increase, 95% confidence interval: 1.02–1.26, p=0.005). PC lesions exhibited significantly higher PSMA-ligand uptake in late scans. However, the magnitude of this increase neither differed significantly across PC lesion types nor correlated with response to PSMA-RLT. Notably, higher SUVmax during standard time-point imaging were associated with an increased likelihood of biochemical response to PSMA-RLT.This publication has 40 references indexed in Scilit:
- Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu‐PSMA‐617 in prostate cancer patientsCPT: Pharmacometrics & Systems Pharmacology, 2023
- Pharmacokinetic studies of [68 Ga]Ga-PSMA-11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue typeEuropean Journal of Nuclear Medicine and Molecular Imaging, 2021
- PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu‐PSMA therapyThe Prostate, 2019
- Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- 18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kineticsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2017
- F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- ggplot22016
- A solution to the problem of separation in logistic regressionStatistics in Medicine, 2002